The rising cost of healthcare is a growing economic and public health crisis that hurts the U.S. economy, threatens individual financial security, compromises care and reduces patient access. Excessive spending on healthcare places significant burdens on American businesses and family budgets and endangers the funding of vital programs such as Medicare and Medicaid.
Our goal is to develop and share specific, commonsense recommendations and policy and practice solutions to that can be advanced and implemented by elected officials, policymakers, health systems, insurers, businesses, patients and other stakeholders. West Health is committed to tracking and measuring progress to hold stakeholders accountable for reducing healthcare costs.
The 2021 Healthcare in America Report details the experiences of an American public that is increasingly burdened by high healthcare costs and growing more and more pessimistic about the future of the nation’s healthcare system.
Key findings include:
West Health focuses on developing evidence-based solutions to drive forward change to ensure that Americans can access the prescription drugs they need at prices they can afford through:
Civica Rx exists in the public interest as a non-stock, non-profit corporation committed to stabilizing the supply of essential generic medications. Founded by seven leading hospital systems concerned about generic drug shortages and three philanthropic members passionate about improving healthcare, including the Gary and Mary West Foundation, Arnold Ventures and the Peterson Center on Healthcare. Since it’s inception, more than 50 Health Systems have joined Civica as Governing, Founding and Partnering members, representing over 1,400 U.S. hospitals and representing one-third of the nation’s licensed hospital beds.
Over 21 million Americans had out-of-pocket spending on medical care plus health insurance premiums totaling 10% or more of their gross family income. West Health’s research with IMPAQ identifies the populations most at risk of high healthcare cost burdens among individuals with Employer Sponsored Insurance.
Three common-sense reforms – lowering the cost of prescription drugs, accelerating the adoption of value-based care models, and increasing price transparency for consumers and employers.